

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 May 2005 (12.05.2005)

PCT

(10) International Publication Number
WO 2005/041964 A1

(51) International Patent Classification⁷: **A61K 31/445**,
A61P 25/04

[GB/GB]; Arakis Ltd., Chesterford Research Park, Little
Chesterford, Saffron Walden, Essex CB10 1XL (GB).

(21) International Application Number:
PCT/GB2004/004459

(74) Agent: **GILL JENNINGS & EVERY**; Broadgate House,
7 Eldon Street, London EC2M 7LH (GB).

(22) International Filing Date: 21 October 2004 (21.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0324583.4 21 October 2003 (21.10.2003) GB
0415267.4 7 July 2004 (07.07.2004) GB

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicant (*for all designated States except US*): **ARAKIS
LTD.** [GB/GB]; Chesterford Research Park, Little Chester-
ford, Saffron Walden, Essex CB10 1XL (GB).

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BREW, John**
[GB/GB]; Arakis Ltd., Chesterford Research Park, Little
Chesterford, Saffron Walden, Essex CB10 1XL (GB). **BANNISTER, Robin, Mark** [GB/GB]; Arakis Ltd.,
Chesterford Research Park, Little Chesterford, Saffron
Walden, Essex CB10 1XL (GB). **BAXTER, Andrew,
Douglas** [GB/GB]; Arakis Ltd., Chesterford Research
Park, Little Chesterford, Saffron Walden, Essex CB10
1XL (GB). **ROTHAUL, Alan** [GB/GB]; Arakis Ltd.,
Chesterford Research Park, Little Chesterford, Saffron
Walden, Essex CB10 1XL (GB). **LYNE, Michael, Harvey**

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: THE USE OF IFENPRODRIL IN THE TREATMENT OF PAIN

(57) Abstract: Ifenprodil is useful for the treatment of pain.

WO 2005/041964 A1

THE USE OF IFENPRODIL IN THE TREATMENT OF PAIN

Field of the Invention

This invention relates to the use of a known compound for the treatment of pain.

5 Background of the Invention

N-methyl-D-aspartate (NMDA) receptor antagonists have been long known to exhibit anti-nociceptive effects, and a number have proven efficacy in the treatment of a number of neuropathies, including postherpetic neuralgia, central pain caused by spinal cord injury and phantom limb pain. The NMDA
10 receptor antagonist dextrorphan is disclosed for the treatment of pain in EP-A-0615749 and also, along with a number of other such compounds (including ifenprodil), in WO-A-97/14415. Unfortunately, most agents which block the NMDA receptor also induce unacceptable side-effects at analgesic doses, including memory impairment, ataxia, hallucinations and dysphoria, which
15 prohibit their widespread use.

Ifenprodil, i.e. 2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)-1-propanol, selectively blocks NR2B-containing NMDA receptors in a voltage-independent and non-competitive manner (Gallagher *et al.*, 1996, J. Biol. Chem. 271(16):9603-9611) and exhibits anti-nociceptive activity in animal models of
20 acute and chronic pain (Taniguchi *et al.*, 1997, Brit. J. Pharmacol. 122, 809-812; Boyce *et al.*, 1999, Neuropharmacology 38:611-623). Ifenprodil (as ifenprodil tartrate) is commercially available as a racemic mixture of the *erythro* diastereomer.

Ifenprodil also exhibits potent alpha-1 adrenergic receptor binding
25 properties (Chenard *et al.*, 1991, J. Med. Chem. 34 (10):3085-3090) which can cause hypotension and syncope in some recipients. It is also reported by Chenard *et al.* that the *threo* isomers of ifenprodil have selectivity for the NMDA receptor over the alpha-1 adrenoreceptor.

WO03/092689 describes the utility of ifenprodil in the treatment of
30 neuropathic pain. Intranasal administration (and other route, preferably avoiding first-pass metabolism) are described.

Summary of the Invention

The present invention is based on the discovery that ifenprodil has utility in the treatment of pain, especially non-neuropathic pain conditions, including post-operative pain, acute pain, chronic benign and cancer pain. Accordingly, ifenprodil can be used to boost analgesia during intermittently uncontrollable episodes (breakthroughs) found in certain painful conditions, e.g. the conditions known as episodic or breakthrough pain. These conditions include chronic benign pain and cancer pain. The chronic benign pain states can be categorised as musculoskeletal, visceral, and headache pain and include conditions such as osteoarthritis, chronic pancreatitis, and chronic migraine. Cancer pain conditions are associated with the malignant growth of tumours both primary and metastatic in nature. The condition is thought to be associated with either pressure on normal tissue (invasion) or by the release of pro-nociceptive mediators in and around the tumour. Pain conditions to be treated include also those associated with inflammation, e.g. as in osteoarthritis.

Description of Preferred Embodiments

Ifenprodil has two chiral centres. Any reference herein to ifenprodil should be understood as a reference to any enantiomer or mixture thereof. Any enantiomer may be substantially free of others, e.g. in an enantiomeric excess of at least 80%, preferably at least 90% and more preferably at least 95%. Similarly, any mixture of diastereomers may be substantially free of the other. The *threo* form, and in particular the (-)-*threo* form, may be preferred in certain cases; the (-)-*erythro* form may be preferred in others.

The ifenprodil may be in the form of the free base or any pharmaceutically acceptable salt, e.g. the citrate or tartrate, or in the form of a metabolite or prodrug. Such forms are known to those of ordinary skill in the art.

The active agent may be administered by, for example, the oral, topical, dermal, ocular, intravenous, intraarticular, rectal, vaginal, inhalation, intranasal, sublingual or buccal route. The amount of active ingredient that is used can be chosen by the skilled person having regard to the usual factors.

For use, the active agent is typically formulated, e.g. with a conventional diluent or carrier, or as a patch, as a medicament adapted to be delivered by the

chosen route. Such formulations are known to those skilled in the art, and will be chosen according to the usual considerations such as the potency of the drug, the severity of the condition and the route of administration.

Ifenprodil is preferably administered sublingually, intranasally, buccally
5 or by the pulmonary or any other route that avoids first-pass metabolism. Sublingual or nasal delivery, for example, can introduce significant concentrations of ifenprodil and its isomers to NMDA receptors whilst reducing side-effects caused by the unwanted alpha-1 adrenoreceptor-binding activity. In this context, a typical daily dose is less than 60 mg, e.g. 1 to 50 mg, ifenprodil;
10 a higher dose, e.g. up to 500 mg, may be used, especially if first-pass metabolism is not avoided.

In particular, it would be of benefit to administer ifenprodil in a manner that reduced peripheral exposure to vascular smooth muscle (minimise effect on vascular tone), while maximising the concentrations in the CNS (maximise
15 analgesia). This may be done by, for example, pulmonary, sublingual or nasal delivery, reducing systemic load, while maximising the concentration of drug in the CNS. By way of example only, a composition for intranasal delivery comprises, in addition to ifenprodil, one or more of a solubility enhancer such as propylene glycol, a humectant such as mannitol, a buffer and water. A
20 mucoadhesive agent may also be used.

Ifenprodil has very poor pharmacokinetics, with very high first-pass metabolism (5% bioavailability and a short half life; $t_{1/2}$ 1 hour). Consequently, administering ifenprodil orally, to treat a chronic condition like neuropathic pain, may require high and frequent doses. Dermal administration, e.g. by the use of
25 a dermal patch, allows chronic dosing of this compound, while avoiding first-pass metabolism and so lowering the dose. Additionally, there is the potential of removing the dose from the circulation rapidly at the end of the treatment period.

Another preferred route of administration is sublingual. A suitable formulation for this purpose may contain components known to those skilled in
30 the art.

It will often be advantageous to use ifenprodil in combination with another drug used for pain therapy. Such another drug may be an opiate or a non-opiate such as baclofen.

The following Examples illustrate the invention.

5 Example 1

This Example is of a composition suitable for intranasal delivery. In this Example, 1-10 mg ifenprodil, preferably as (-)-threo-ifenprodil citrate, is included in 100 µl of:

	Excipient:	%w/w	
10	Benzalkonium chloride	0.02	Preservative
	Propylene Glycol	25	Solubility Enhancer
	Mannitol	15	Humectant
	Na ₂ PO ₄ (0.2M)	25.2	
	Citric Acid (0.1M)	10.0	
15	Deionised water	24.6	(pH6.5 buffer)

Example 2

In a test on the effect of ifenprodil on the intraplantar carrageenan-induced paw withdrawal latency in the rat, the erythro racemate of ifenprodil was
 20 demonstrated to be markedly analgesic when administered via both the intraperitoneal (10 mg/kg and 30 mg/kg) and the intranasal route (2.5 mg/rat and 7.5 mg/rat); see Figure 1. The intranasal route proved to be at least equivalent if not superior to the intraperitoneal route.

(-) Threo-ifenprodil has also been demonstrated to have excellent efficacy
 25 in the intraplantar carrageenan-induced paw withdrawal latency in the rat at low doses (0.1, 0.3, 1 and 3 mg/kg intravenous); see Figure 2. These results indicate that (-) threo-ifenprodil, when given through the nasal route, will have excellent efficacy in this pain model and in chronic pain conditions.

More particularly, Fig. 1 is a graph showing the effect of (-) threo-
 30 ifenprodil when given intranasally or intraperitoneally at 10 and 30 mg/kg on the % change of pressure-induced paw withdrawal latency on the intraplantar carrageenan administered paw in the rat (250 g).

Fig. 2 is a graph showing the effect of (-) threo-ifenprodil when given intravenously at 0.1 to 3 mg/kg on the % change of pressure-induced paw withdrawal latency on the intraplantar carrageenan administered paw in the rat.

CLAIMS

1. Use of ifenprodil for the manufacture of a medicament for the treatment of pain.
2. Use according to claim 1, for the treatment of intermittent or episodic pain
- 5 experienced by a patient undergoing chronic pain treatment.
3. Use according to claims 1 or claim 2, wherein the pain is chronic benign pain.
4. Use according to claim 3, wherein the pain is related to a musculoskeletal, visceral or headache condition.
- 10 5. Use according to claim 4, wherein the condition is osteoarthritis, chronic pancreatitis or chronic migraine.
6. Use according to claim 2, wherein the pain is episodic or breakthrough pain in cancer.
7. Use according to claim 1, wherein the pain is acute pain.
- 15 8. Use according to claim 1, wherein the pain is post-operative pain.
9. Use according to any preceding claim, wherein the ifenprodil is in the form of either or both *threo* enantiomers.
10. Use according to claim 9, wherein the ifenprodil is (-)-*threo*-ifenprodil.
11. Use according to any preceding claim, wherein the medicament is for
- 20 administration via a route that avoids first-pass metabolism.
12. Use according to claim 11, wherein the route is sublingual.
13. Use according to claim 11, wherein the route is intranasal.
14. Use according to claim 11, wherein the route is dermal.
15. Use according to any of claims 11 to 14, wherein the medicament is in the
- 25 form of a unit dosage containing less than 60 mg ifenprodil.
16. A composition suitable for intranasal delivery, which comprises an aqueous solution of ifenprodil, a solubility enhancer and a humectant.
17. A composition according to claim 16, wherein the ifenprodil is (-)-*threo*-ifenprodil.
- 30 18. A composition according to claim 17, wherein the ifenprodil is (-)-*erythro*-ifenprodil.

1/2




Fig. 1

2/2




Fig. 2

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/004459

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/445 A61P25/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/092689 A (BAXTER ANDREW DOUGLAS ; LYNE MICHAEL HARVEY (GB); BREW JOHN (GB); ARAK) 13 November 2003 (2003-11-13) cited in the application claims 1-13	1-18
X	WO 97/14415 A (FAULDING F H & CO LTD ; SMITH IAN KEITH (AU); HEINICKE GRANT WAYNE (AU) 24 April 1997 (1997-04-24) cited in the application claims 30,48-50	1-10
X	WO 99/44610 A (MERCK SHARP & DOHME ; BOYCE SUSAN (GB)) 10 September 1999 (1999-09-10) page 4, line 30 - page 5, line 24; claims 1,2,5-8 page 10, lines 11-19; examples 3,4A,5; table 1	1-18
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

7 December 2004

Date of mailing of the international search report

07/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Tardi, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/004459

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/44640 A (MERCK SHARP & DOHME ; BOYCE SUSAN (GB)) 10 September 1999 (1999-09-10) page 4, line 29 - page 5, line 9; claims 1,2,6,7 page 6, lines 21-24 page 24, lines 4-16; examples 3,4A,5; table 1 -----	1-18
X	PATENT ABSTRACTS OF JAPAN vol. 0103, no. 77 (C-392), 16 December 1986 (1986-12-16) & JP 61 172820 A (GRELAN PHARMACEUT CO LTD), 4 August 1986 (1986-08-04) abstract -----	1,3,4
X	CHIZH B A ET AL: "NMDA receptor antagonists as analgesics: focus on the NR2B subtype" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 22, no. 12, 1 December 2001 (2001-12-01), pages 636-642, XP004323807 ISSN: 0165-6147 abstract page 637, column 2, lines 6-23; table 1 page 640, column 2, paragraph 4 -----	1-18
X	BERNARDI MARA ET AL: "Blockage of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 298, no. 1, 1996, pages 51-55, XP002309375 ISSN: 0014-2999 abstract page 53, column 2, paragraph 3 -----	1-18

INTERNATIONAL SEARCH REPORT

Int. Patent Application No
PCT/GB2004/004459

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03092689	A	13-11-2003	WO 03092689 A1	13-11-2003
WO 9714415	A	24-04-1997	AU 708408 B2	05-08-1999
			AU 7207896 A	07-05-1997
			WO 9714415 A1	24-04-1997
			CA 2235071 A1	24-04-1997
			EP 0858334 A1	19-08-1998
			US 6194000 B1	27-02-2001
WO 9944610	A	10-09-1999	AU 3260099 A	20-09-1999
			CA 2321685 A1	10-09-1999
			EP 1059923 A1	20-12-2000
			WO 9944610 A1	10-09-1999
			JP 2002505287 T	19-02-2002
			US 6538008 B1	25-03-2003
			ZA 9901745 A	06-09-1999
WO 9944640	A	10-09-1999	AT 266420 T	15-05-2004
			AU 753079 B2	10-10-2002
			AU 2632999 A	20-09-1999
			CA 2321687 A1	10-09-1999
			DE 69917230 D1	17-06-2004
			EP 1058559 A1	13-12-2000
			WO 9944640 A1	10-09-1999
			JP 2002505306 T	19-02-2002
			ZA 9901744 A	13-09-1999
JP 61172820	A	04-08-1986	NONE	